Published by Josh White on 4th January 2024
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.
URL: http://www.digitallook.com/dl/news/story/34004821/...